The Devyser blog

Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with...

Devyser has today been certified under the new, more comprehensive IVD Regulation that came into...

"Devyser reported another quarter of strong organic growth, which again saw record-breaking sales....

On September 1, Camilla Wiberg will take up the newly established position as Chief HR Officer...

Devyser announces a strengthening of its commercial organization with the appointment of Theis...

May 11, 2022 08:00

Stockholm, February 7, 2022

We are extremely proud to have been recognized, once again, as one of Sweden's Best Workplaces!...

Devyser has been awarded a funding of EUR 750,000 through the Eurostars-2 program and will join its...

Dr. Dan Hauzenberger, Medical Director, Section of Transplantation Immunology at Sweden’s...

We’re happy to announce that we’ve received certification for the successful completion of a...